anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A first-line chemotherapy regimen for oral squamous cell carcinoma involves combining paclitaxel with platinum agents. PD-1 antibodies have shown promise in cases where the cancer has recurred, metastasized, or didn't respond to platinum-based treatments. Research is ongoing on using immune induction therapy with surgery or chemoradiotherapy for locally advanced, resectable oral squamous cell carcinoma. Trastuzumab, in combination with standard chemotherapy, is being explored as an induction treatment for patients needing mandibulectomy due to tumor proximity to the mandible. This study is a prospective, single-arm, single-center Phase II explora.
A 30-year-old G4P1+2(1 alive) woman with a history of cervical incompetence initially presented at a gestational age (GA) of 10 weeks and 6 days with lower abdominal pain and was managed conservatively as a case of threatened miscarriage. She re-presented two weeks later and was admitted on account of lower abdominal pain and spotting per vagina of 4hrs duration. An obstetric ultrasound revealed an intrauterine pregnancy invading the posterior myometrium with thinning of the uterine wall and hemoperitoneum. She subsequently had an exploratory laparotomy, evacuation of the hemoperitoneum, separation of the fetus from the myometrium, and repair with no. 2 vicryl suture. The patient recovered satisfactorily and had two units of whole blood transfused. She was managed with analgesics, hematinics and broad-spectrum antibiotics. She was discharged on the 4th post-operative day to be followed up at the gynaecological clinic.
The invention relates to an herbal strengthening Chinese medicine composition and a preparation method thereof. The herbal strengthening Chinese medicine composition mainly consists of codonopsis pilosula, astragalus root, rehmannia root, Chinese angelica, polyporus, forsythia and the like, and has the efficacies of strengthening the body resistance to consolidate the constitution, clearing away heat and toxic material, invigorating blood circulation for detumescence, and promoting diuresis for stranguria. The herbal strengthening Chinese medicine composition is clinically used for infectious bursal disease for chicken to improve the immunological competence for the chicken and prevent immunological suppression caused by the infectious bursal disease and the like. The strengthening herbal Chinese medicine which is developed by modern Chinese medicine development technology and is based on the Chinese medical principle reserves the combination effect of Chinese medicine differentiation treatment to prepare granular medicine. The effective components of major drugs in the herbal strengthening Chinese medicine composition are subjected to quantitative and semi-quantitative tests by a modern technological method. The herbal Chinese medicine composition has definite efficacy through clinical verification, so the composition is a green animal medicine without environmental disruption or drug residual.
The present invention relates to a cefaclor capsule and a preparation method thereof. The cefaclor capsule is composed by the following components by weight: 100 parts of cefaclor, 5-100 parts of pregelatinized starch, 1-5 parts of silica and 0.5-2.5 parts of magnesium stearate. The preparation method comprises: (1) sieving the cefaclor after pulverization; (2) mixing pregelatinized starch and silica with the sieved cefaclor powder uniformly; (3) adding magnesium stearate and mixing uniformly; and (4) making the mixed powder into capsules, and packing the qualified capsules into resulting products after detection. The sources of raw and auxiliary materials selected by the present invention are convenient. The auxiliary materials are few in types, are all commonly used auxiliary materials for preparations, and are low in prices. The production process is simple, and the operation is convenient and fast. The preparation process is simple, easy in operation, low in cost, and high in yield, and is suitable for large-scale industrial production.
Objective. Accurate and timely prediction of epileptic seizures is crucial for empowering patients to mitigate their impact or prevent them altogether. Current studies predominantly focus on short-term seizure predictions, which causes the prediction time to be shorter than the onset of antiepileptic, thus failing to prevent seizures. However, longer epilepsy prediction faces the problem that as the preictal period lengthens, it increasingly resembles the interictal period, complicating differentiation.Approach. To address these issues, we employ the sample entropy method for feature extraction from electroencephalography (EEG) signals. Subsequently, we introduce the anchoring temporal convolutional networks (ATCN) model for longer-term, patient-specific epilepsy prediction. ATCN utilizes dilated causal convolutional networks to learn time-dependent features from previous data, capturing temporal causal correlations within and between samples. Additionally, the model also incorporates anchoring data to enhance the performance of epilepsy prediction further. Finally, we proposed a multilayer sliding window prediction algorithm for seizure alarms.Main results. Evaluation on the Freiburg intracranial EEG dataset shows our approach achieves 100% sensitivity, a false prediction rate (FPR) of 0.09 per hour, and an average prediction time (APT) of 98.92 min. Using the CHB-MIT scalp EEG dataset, we achieve 97.44% sensitivity, a FPR of 0.12 per hour, and an APT of 93.54 min.Significance. These results demonstrate that our approach is adequate for seizure prediction over a more extended prediction range on intracranial and scalp EEG datasets. The APT of our approach exceeds the typical onset time of antiepileptic. This approach is particularly beneficial for patients who need to take medication at regular intervals, as they may only need to take their medication when our method issues an alarm. This capability has the potential to prevent seizures, which will greatly improve patients' quality of life.
This will be a single center randomized trial. The study will be conducted using block randomization, with two six-month blocks of patient enrollment. The first block will consist of patients undergoing treatment of the above-mentioned fractures with normal standard of care pain management protocol (pre-, intra-, and postoperatively). The second block will consist of patients undergoing treatment the same fractures with opioid-free pain management protocol (pre-, intra-, and postoperatively). Block selection will be determined based on the date of the surgery. However, patients initially assigned to the opioid-free protocol that have CKD/laboratory evidence of poor renal function (ie, elevated BUN/Creatinine) or laboratory evidence of liver function issues (ie, cirrhosis, hypoalbuminemia, elevated liver transaminases, elevated GGT) will crossover to the opioid group as NSAID use and acetaminophen use, respectively, are contraindicated. The use of block randomization will preclude the need for the study coordinator to perform any sort of individual randomization or sealed envelope use for treatment assignment. For subjects who meet eligibility criteria, study informed consent will be obtained at the same time as surgical consent. Patients in the standard of care study block will undergo KUMC's normal pain management strategy. Patients in the opioid-free study block will receive the same pain-management drugs as the opioid group aside from receiving opioids; all other medical care will be standard in this group. Postoperative weightbearing, immobilization, perioperative antibiotics, drain usage, and discharge criteria will be determined by institutional protocols and will remain the same for each block. All patients will be started on postoperative chemical anticoagulation prophylaxis as determined by their fracture pattern and medical comorbidities. Patients will be clinically monitored for signs of venous thromboembolism and appropriate diagnostic screening will be utilized as necessary. Wound complications will be monitored by the treating surgeon and managed as necessary. The study team also plans to record patient specific factors including age, sex, BMI, smoking status, comorbidities, and operative time. These variables will be analyzed independently to detect any correlation with the two pain management protocols.
The patient will receive 60 mL of 1% Zinc oxide nanoparticles solution. They will be instructed to apply 0.5 mL of the solution to the lesion twice daily for a consecutive period of 8 weeks.
BACKGROUND: Based on bioinformatics research of NUDT21 in pan-cancer, we aimed to clarify the mechanism of NUDT21 in HHNC by experiment.
METHODS: The correlation between differential expression of NUDT21 in pan-cancer and survival prognosis, genomic instability, tumor stemness, DNA repair, RNA methylation and with immune microenvironment were analyzed by the application of different pan-cancer analysis web databases. In addition, immunohistochemistry staining and genetic detection of NUDT21 in HHNCC tumor tissues by immunohistochemistry and qRT-PCR. Then, through in vitro cell experiments, NUDT21 was knocked down by lentivirus to detect the proliferation, cycle, apoptosis of FaDu and CNE-2Z cells, and finally by PathScan intracellular signaling array reagent to detect the apoptotic protein content.
RESULTS: Based on the pan-cancer analysis, we found that elevated expression of NUDT21 in most cancers was significantly correlated with TMB, MSI, neoantigens and chromosomal ploidy, and in epigenetics, elevated NUDT21 expression was strongly associated with genomic stability, mismatch repair genes, tumor stemness, and RNA methylation. Based on immunosuppressive score, we found that NUDT21 plays an essential role in the immunosuppressive environment by suppressing immune checkpointing effect in most cancers. In addition, using HHNSCC as a study target, PCR and pathological detection of NUDT21 in tumor tissues was significantly increased than that in paracancerous normal tissues. In vitro cellular assays, silencing NUDT21 inhibited proliferation and promoted apoptosis in FaDu and CNE-2Z cells, and blocked the cell cycle in the G2/M phase. Therefore, the experiments confirmed that NUDT21 promotes the proliferation of FaDu by suppressing the expression of apoptotic.
Group (Ⅲ) (diabetic patients): n=10 subdivided into Test side: received MD plus subgingival application of PRP. Control side: received MD only.
BACKGROUND: There has been a proliferation of physicians of different levels of experience and training offering nonsurgical cosmetic procedures. Rising demand, compounded by increasing utilization of new and existing technologies by numerous physician specialties, compels discussion of adequate standardized training and patient safety.
METHODS: A retrospective chart review of patients who presented to our single site dermatology clinic for managment of complications following chemical peel, laser or energy-based device treatments performed by core cosmetic physicians between the years of 2013 and 2024 was conducted. Core cosmetic physicians included plastic surgery, facial surgery/otolaryngology, oculoplastic surgery, and dermatology. Charts were reviewed for documentation of the type of complication, procedure causing the complication, and physician credentials, and referral source.
RESULTS: Twenty-five patients were identified as having complications from chemical peeling, laser treatment or energy-based devices. Devices implicated included CO2 laser (fractional or fully ablative), chemical peels, 1064 nm long-pulsed Nd:YAG laser, 1320 nm Nd:YAG laser, intense pulsed light, 595 nm pulsed dye laser, Q-switched Nd:YAG laser, radiofrequency with and without microneedling, and 1550 nm erbium-doped fiber laser. Complications included hypertrophic scarring, atrophic scarring, post-inflammatory erythema, post-inflammatory hyperpigmentation, and post-inflammatory hypopigmentation.
CONCLUSIONS: Even in experienced hands, complications can arise. It is imperative that all physicians offering cosmetic treatments are equipped to recognize clinical endpoints, identify and manage complications, or make a timely referral to decrease the risk of a permanent and potentially devastating esthetic outcome for patients.
<P>PROBLEM TO BE SOLVED: To provide particles containing a lipophilic compound and having a narrow particle size distribution by covering the surfaces of droplets of the lipophilic compound unstable to water, light, oxygen, or the like.  <P>SOLUTION: A spiral gas flow is generated in a spray tower 1 by introducing a gas containing starch dispersed therein from a spout 3 installed in a side surface in the spray tower 1. An emulsified dispersion obtained by dispersing fat-soluble vitamins is sprayed from a nozzle 2 in the gas flow to form coated particles of the fat-soluble vitamins having the surface coated with the coating agent (starch). By the generation of the spiral gas flow, nearly uniform coated particles are formed because the retention time of the emulsified dispersion and the coating agent in the spray tower 1 is prolonged. As a result, the unstable fat-soluble vitamins are provided as coated particles having the narrow particle size distribution.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
FIELD: medicine. SUBSTANCE: according to the suggested method strain 3 of serotype is cultivated upon fibroblasts of quail embryos, and strain 2 of serotype is cultivated upon fibroblasts of chicken embryos. Fibroblasts of quail embryos and fibroblasts of chicken embryos are infected with industrial viral reproductions without their preliminary regeneration. Target product is obtained due to combining 2 cu. cm VGI strain and 1 cu. cm VGK strain. Vaccine obtained is of stable infectious and immunogenic activity. EFFECT: higher efficiency. 5 cl, 3 tbl
The 28-kDa outer membrane proteins (P28) of  Ehrlichia chaffeensis  are encoded by a multigene family consisting of 21 members located in a 23-kb DNA fragment in the genome of  E. chaffeensis . Fifteen of these proteins are claimed herein as novel sequences. The amino acid sequence identity of the various P28 proteins was 20-83%. Six of 10 tested p28 genes were actively transcribed in cell culture grown  E. chaffeensis . RT-PCR also indicated that each of the p28 genes was monocistronic. These results suggest that the p28 genes are active genes and encode polymorphic forms of the P28 proteins. The P28s were also divergent among different isolates of  E. chaffeensis . The large repertoire of the p28 genes in a single ehrlichial organism and antigenic diversity of the P28 among the isolates of  E. chaffeensis  suggest that the P28s may be involved in immune avoidance.
Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.
The cornerstones of good health are exercise, proper food, and sound nutrition. Physical exercise should be a lifelong routine, supported by proper food selections to satisfy nutrient requirements based on energy needs, energy management, and variety to achieve optimal metabolism and physiology. The human body is sustained by intermediary and systemic metabolism integrating the physiologic processes for cells, tissues, organs, and systems. Recently, interest in specific metabolites, growth factors, cytokines, and hormones called exerkines has emerged to explain cooperation between nutrient supply organs and the brain during exercise. Exerkines consist of different compounds described as signaling moiety released during and after exercise. Examples of exerkines include oxylipin 12, 13 diHOME, lipid hormone adiponectin, growth factor BDNF, metabolite lactate, reactive oxygen species (ROS), including products of fatty acid oxidation, and cytokines such as interleukin-6. At this point, it is believed that exerkines are immediate, fast, and long-lasting factors resulting from exercise to support body energy needs with an emphasis on the brain. Although exerkines that are directly a product of macronutrient metabolism such as lactate, and result from catabolism is not surprising. Furthermore, other metabolites of macronutrient metabolism seem to be candidate exerkines. The exerkines originate from muscle, adipose, and liver and support brain metabolism, energy, and physiology. The purpose of this review is to integrate the actions of exerkines with respect to metabolism that occurs during exercise and propose other participating factors of exercise and brain physiology. The role of diet and macronutrients that influence metabolism and, consequently, the impact of exercise will be discussed. This review will also describe the evidence for PUFA, their metabolic and physiologic derivatives endocannabinoids, and oxylipins that validate them being exerkines. The intent is to present additional insights to better understand exerkines with respect to systemic metabolism.
Group 2 (G2) - 80 eligible participants will receive training in CR. These participants will use CR while receiving scalp electrical stimulation over their individual dlPFC target and will partake in short term and long term follow up testing.
This study aimed at understanding the predictive potential of genetic risk scores (GRS) for diabetic kidney disease (DKD) progression in patients with type 2 diabetes mellitus (T2DM) and Major Cardiovascular Events (MCVE) and All-Cause Mortality (ACM) as secondary outcomes. We evaluated 30 T2DM and CKD GWAS-derived single nucleotide polymorphisms (SNPs) and their association with clinical outcomes in a central European cohort (n = 400 patients). Our univariate Cox analysis revealed significant associations of age, duration of diabetes, diastolic blood pressure, total cholesterol and eGFR with progression of DKD (all P < 0.05). However, no single SNP was conclusively associated with progression to DKD, with only CERS2 and SHROOM3 approaching statistical significance. While a single SNP was associated with MCVE - WSF1 (P = 0.029), several variants were associated with ACM - specifically CANCAS1, CERS2 and C9 (all P < 0.02). Our GRS did not outperform classical clinical factors in predicting progression to DKD, MCVE or ACM. More precisely, we observed an increase only in the area under the curve (AUC) in the model combining genetic and clinical factors compared to the clinical model alone, with values of 0.582 (95 % CI 0.487-0.676) and 0.645 (95 % CI 0.556-0.735), respectively. However, this difference did not reach statistical significance (P = 0.06). This study highlights the complexity of genetic predictors and their interplay with clinical factors in DKD progression. Despite the promise of personalised medicine through genetic markers, our findings suggest that current clinical factors remain paramount in the prediction of DKD. In conclusion, our results indicate that GWAS-derived GRSs for T2DM and CKD do not offer improved predictive ability over traditional clinical factors in the studied Czech T2DM population.
Adverse events that are clearly related to Sotalol AF are those which are typical of its Class II (beta-blocking) and Class III (cardiac action potential duration prolongation) effects. The common documented beta-blocking adverse events (bradycardia, dyspnea, and fatigue) and Class III effects (QT interval prolongation) are dose related.

In a pooled clinical trial population consisting of four placebo-controlled studies with 275 patients with AFIB/AFL treated with 160 to 320 mg doses of Sotalol AF, the following adverse events were reported at a rate of 2% or more in the 160 to 240 mg treated patients and greater than the rate in placebo patients (See Table 8). The data are presented by incidence of events in the Sotalol AF and placebo groups by body system and daily dose. No significant irreversible non-cardiac end-organ toxicity was observed.

Overall, discontinuation because of unacceptable adverse events was necessary in 17% of the patients, and occurred in 10% of patients less than two weeks after starting treatment. The most common adverse events leading to discontinuation of Sotalol AF were: fatigue 4.6%, bradycardia 2.4%, proarrhythmia 2.2%, dyspnea 2%, and QT interval prolongation 1.4%.

In clinical trials involving 1292 patients with sustained VT/VF, the common adverse events (occurring in ≥2% of patients) were similar to those described for the AFIB/AFL population.

Occasional reports of elevated serum liver enzymes have occurred with sotalol therapy but no cause and effect relationship has been established. One case of peripheral neuropathy which resolved on discontinuation of sotalol and recurred when the patient was rechallenged with the drug was reported in an early dose tolerance study. Elevated blood glucose levels and increased insulin requirements can occur in diabetic patients.

In an unblinded multicenter trial of 25 patients with SVT and/or VT receiving daily doses of 30, 90 and 210 mg/m2 with dosing every 8 hours for a total of 9 doses, no Torsades de Pointes or other serious new arrhythmias were observed. One (1) patient, receiving 30 mg/m2 daily, was discontinued because of increased frequency of sinus pauses/bradycardia. Additional cardiovascular AEs were seen at the 90 and 210 mg/m2 daily dose levels. They included QT prolongations (2 patients), sinus pauses/bradycardia (1 patient), increased severity of atrial flutter and reported chest pain (1 patient). Values for QTc ≥525 msec were seen in 2 patients at the 210 mg/m2 daily dose level. Serious adverse events including death, Torsades de Pointes, other proarrhythmias, high-degree A-V blocks and bradycardia have been reported in infants and/or children.
The present disclosure provides, according to some embodiments, methods and systems for selectively reducing, blocking or inhibiting at least part of the neural activity in an organ of a subject. In preferred embodiments, the method and system are used for selectively blocking at least part of the neural activity in a duodenum of a subject in need thereof. According to some embodiments, the selective blocking occurs through use of laser radiation. According to some embodiments, the selective blocking occurs through use of ultrasound energy. According to some embodiments, the selective blocking comprises causing damage to at least part of sensory nerves located within a target area while maintaining functional activity of tissue surrounding the sensory nerves by means of shielding it from the effects of laser radiation. According to some embodiments, the sensory nerves include neurons configured to transmit signals triggered by food passing through the duodenum, such as, but not limited to, neurohormonal signals.
This is a postmarket medical device study. This study will examine treatment outcomes for patients with TRD who are randomized to VNS Therapy administered at different amounts of electrical charge. The Sponsor, Cyberonics, provides funding for this study. Patients are followed for 54 weeks, 50 of those weeks are following implantation of the VNS Therapy system. No study sites will be permitted to enroll study subjects until Institutional Review Board (IRB) approval has been received. Sites are permitted to be approved by a local or a central IRB.